Copyright Reports & Markets. All rights reserved.

Asia-Pacific Oncology Biosimilars Market Report 2019

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Oncology Biosimilars Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 G-CSF Market Performance (Volume)
      • 2.1.2 Hematopoietic Agents Market Performance (Volume)
      • 2.1.3 Monoclonal Antibodies Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.2.1 G-CSF Market Performance (Value)
      • 2.2.2 Hematopoietic Agents Market Performance (Value)
      • 2.2.3 Monoclonal Antibodies Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Retail Pharmacies Market Performance (Volume)
      • 3.1.2 Hospital Pharmacies Market Performance (Volume)
      • 3.1.3 Online Pharmacies Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Celltrion Inc.
      • 4.1.1 Celltrion Inc. Profiles
      • 4.1.2 Celltrion Inc. Product Information
      • 4.1.3 Celltrion Inc. Oncology Biosimilars Business Performance
      • 4.1.4 Celltrion Inc. Oncology Biosimilars Business Development and Market Status
    • 4.2 Pfizer Inc.
      • 4.2.1 Pfizer Inc. Profiles
      • 4.2.2 Pfizer Inc. Product Information
      • 4.2.3 Pfizer Inc. Oncology Biosimilars Business Performance
      • 4.2.4 Pfizer Inc. Oncology Biosimilars Business Development and Market Status
    • 4.3 Biocon
      • 4.3.1 Biocon Profiles
      • 4.3.2 Biocon Product Information
      • 4.3.3 Biocon Oncology Biosimilars Business Performance
      • 4.3.4 Biocon Oncology Biosimilars Business Development and Market Status
    • 4.4 BIOCAD
      • 4.4.1 BIOCAD Profiles
      • 4.4.2 BIOCAD Product Information
      • 4.4.3 BIOCAD Oncology Biosimilars Business Performance
      • 4.4.4 BIOCAD Oncology Biosimilars Business Development and Market Status
    • 4.5 Apotex Inc.
      • 4.5.1 Apotex Inc. Profiles
      • 4.5.2 Apotex Inc. Product Information
      • 4.5.3 Apotex Inc. Oncology Biosimilars Business Performance
      • 4.5.4 Apotex Inc. Oncology Biosimilars Business Development and Market Status
    • 4.6 Dr. Reddy's Laboratories Ltd.
      • 4.6.1 Dr. Reddy's Laboratories Ltd. Profiles
      • 4.6.2 Dr. Reddy's Laboratories Ltd. Product Information
      • 4.6.3 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Business Performance
      • 4.6.4 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Business Development and Market Status
    • 4.7 Sandoz International GmbH
      • 4.7.1 Sandoz International GmbH Profiles
      • 4.7.2 Sandoz International GmbH Product Information
      • 4.7.3 Sandoz International GmbH Oncology Biosimilars Business Performance
      • 4.7.4 Sandoz International GmbH Oncology Biosimilars Business Development and Market Status
    • 4.8 Intas Pharmaceuticals Ltd.
      • 4.8.1 Intas Pharmaceuticals Ltd. Profiles
      • 4.8.2 Intas Pharmaceuticals Ltd. Product Information
      • 4.8.3 Intas Pharmaceuticals Ltd. Oncology Biosimilars Business Performance
      • 4.8.4 Intas Pharmaceuticals Ltd. Oncology Biosimilars Business Development and Market Status
    • 4.9 STADA Arzneimittel AG
      • 4.9.1 STADA Arzneimittel AG Profiles
      • 4.9.2 STADA Arzneimittel AG Product Information
      • 4.9.3 STADA Arzneimittel AG Oncology Biosimilars Business Performance
      • 4.9.4 STADA Arzneimittel AG Oncology Biosimilars Business Development and Market Status
    • 4.10 Teva Pharmaceutical Industries Ltd.
      • 4.10.1 Teva Pharmaceutical Industries Ltd. Profiles
      • 4.10.2 Teva Pharmaceutical Industries Ltd. Product Information
      • 4.10.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Business Performance
      • 4.10.4 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Business Development and Market Status

    5 Market Performance for Manufacturers

    • 5.1 Asia-Pacific Oncology Biosimilars Sales (K Units) and Market Share by Manufacturers 2014-2020
    • 5.2 Asia-Pacific Oncology Biosimilars Revenue (M USD) and Market Share by Manufacturers 2014-2020
    • 5.3 Asia-Pacific Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
    • 5.4 Asia-Pacific Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 China Market Performance for Manufacturers
      • 6.1.1 China Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.1.2 China Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.1.3 China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.1.4 China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.1.5 Market Concentration
    • 6.2 Japan Market Performance for Manufacturers
      • 6.2.1 Japan Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.2.2 Japan Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.2.3 Japan Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.2.4 Japan Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.2.5 Market Concentration
    • 6.3 South Korea Market Performance for Manufacturers
      • 6.3.1 South Korea Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.3.2 South Korea Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.3.3 South Korea Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.3.4 South Korea Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.3.5 Market Concentration
    • 6.4 India Market Performance for Manufacturers
      • 6.4.1 India Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.4.2 India Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.4.3 India Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.4.4 India Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.4.5 Market Concentration
    • 6.5 Southeast Asia Market Performance for Manufacturers
      • 6.5.1 Southeast Asia Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.5.2 Southeast Asia Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.5.3 Southeast Asia Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.5.4 Southeast Asia Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.5.5 Market Concentration
    • 6.6 Australia Market Performance for Manufacturers
      • 6.6.1 Australia Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.6.2 Australia Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.6.3 Australia Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.6.4 Australia Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.6.5 Market Concentration
    • 6.7 Market Performance for Manufacturers
      • 6.7.1 Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.7.2 Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.7.3 Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.7.4 Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.8.2 Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.8.3 Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.8.4 Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.8.5 Market Concentration

    7 Asia-Pacific Oncology Biosimilars Market Performance (Sales)

    • 7.1 Asia-Pacific Oncology Biosimilars Sales (K Units) and Market Share by Regions 2014-2020
    • 7.2 Asia-Pacific Oncology Biosimilars Revenue (M USD) and Market Share by Regions 2014-2020
    • 7.3 Asia-Pacific Oncology Biosimilars Price (USD/Unit) by Regions 2014-2020
    • 7.4 Asia-Pacific Oncology Biosimilars Gross Margin by Regions 2014-2020

    8 Development Trend for Regions (Sales)

    • 8.1 Asia-Pacific Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.2 China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.3 Japan Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.4 South Korea Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.5 India Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.6 Southeast Asia Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.7 Australia Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Retail Pharmacies Industry
    • 11.2 Hospital Pharmacies Industry
    • 11.3 Online Pharmacies Industry

    12 Market Forecast 2021-2026

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
      • 12.1.1 Asia-Pacific Oncology Biosimilars Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
      • 12.1.2 Asia-Pacific Oncology Biosimilars Sales (K Units) and Growth Rate 2021-2026
      • 12.1.3 China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.4 Japan Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.5 South Korea Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.6 India Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.7 Southeast Asia Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.8 Australia Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.2 Sales (K Units) and Revenue (M USD) Forecast by Types 2021-2026
      • 12.2.1 Overall Market Performance
      • 12.2.2 G-CSF Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.2.3 Hematopoietic Agents Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.2.4 Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.3 Sales and Growth Rate Forecast by Application 2021-2026
      • 12.3.1 Overall Market Performance
      • 12.3.2 Retail Pharmacies
      • 12.3.3 Hospital Pharmacies
      • 12.3.4 Online Pharmacies
    • 12.4 Price (USD/Unit) and Gross Profit Forecast
      • 12.4.1 Asia-Pacific Oncology Biosimilars Price (USD/Unit) Trend 2021-2026
      • 12.4.2 Asia-Pacific Oncology Biosimilars Gross Profit Trend 2021-2026

    13 Conclusion

    In this report, our team research theAsia-Pacific Oncology Biosimilars market by type, application, region and manufacturer 2014-2020 and forcast 2021-2026. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.

    Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Oncology Biosimilars for these regions, from 2014 to 2026 (forecast), including
    China
    Japan
    South Korea
    India
    Southeast Asia
    Australia

    Asia-Pacific Oncology Biosimilars market competition by top manufacturers/players, with Oncology Biosimilars sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Celltrion Inc.
    Pfizer Inc.
    Biocon
    BIOCAD
    Apotex Inc.
    Dr. Reddy's Laboratories Ltd.
    Sandoz International GmbH
    Intas Pharmaceuticals Ltd.
    STADA Arzneimittel AG
    Teva Pharmaceutical Industries Ltd.

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    G-CSF
    Hematopoietic Agents
    Monoclonal Antibodies

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Oncology Biosimilars for each application, including
    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

    If you have any special requirements, please let us know and we will offer you the report as you want.
    Buy now